XL844
- Generic Name
- XL844
- Drug Type
- Small Molecule
- Background
XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. Known drug targets of XL844 including serine/threonine-protein kinase Chk1 and serine/threonine-protein kinase Chk2.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 28
- Registration Number
- NCT00475917
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Exelixis
- Registration Number
- NCT00234481
- Locations
- 🇺🇸
UCSD Moores Cancer Center, San Diego, California, United States
🇺🇸City of Hope National Cancer Center, Duarte, California, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.